Validation of claims‐based algorithms for rheumatoid arthritis in Japan: Results from the VALIDATE‐J study

Author:

Sugiyama Naonobu1ORCID,Kinjo Mitsuyo2,Jinno Sadao3,de Luise Cynthia4,Morishima Toshitaka5,Higuchi Takakazu6,Katayama Kayoko7,Chen Haoqian8,Nonnenmacher Edward8,Hase Ryota910,Suzuki Daisuke11,Tanaka Yoshiya12ORCID,Setoguchi Soko1013

Affiliation:

1. Inflammation and Immunology, Medical Affairs Pfizer Japan Tokyo Japan

2. Division of Rheumatology Okinawa Chubu Hospital Uruma Okinawa Japan

3. Section of Rheumatology Kobe University School of Medicine Kobe Hyogo Japan

4. Safety Surveillance Research Pfizer Inc New York New York USA

5. Cancer Control Center Osaka International Cancer Institute Osaka Japan

6. Blood Transfusion Department Dokkyo Medical University Saitama Medical Center Koshigaya Saitama Japan

7. Cancer Prevention and Cancer Control Division Kanagawa Cancer Center Research Institute Yokohama Kanagawa Japan

8. Center for Pharmacoepidemiology and Treatment Science Rutgers Institute for Health, Health Care Policy and Aging Research New Brunswick New Jersey USA

9. Department of Infectious Diseases Kameda Medical Center Kamogawa Chiba Japan

10. Department of Infectious Diseases Japanese Red Cross Narita Hospital Narita Chiba Japan

11. Department of Infectious Diseases Fujita Health University Toyoake Aichi Japan

12. First Department of Internal Medicine University of Occupational and Environmental Health Japan Kitakyushu Fukuoka Japan

13. Department of Medicine Rutgers Robert Wood Johnson Medical School and Institute for Health, Rutgers Biomedical and Health Science New Brunswick New Jersey USA

Abstract

AbstractAimValidity of Algorithms in Large Databases: Infectious Diseases, Rheumatoid Arthritis, and Tumor Evaluation in Japan (VALIDATE‐J) study examined algorithms for identifying rheumatoid arthritis (RA) in Japanese claims data.MethodsVALIDATE‐J was a multicenter, cross‐sectional retrospective study. Disease‐identifying algorithms were used to detect RA diagnosed between January 2012 and December 2016 using claims data from two Japanese hospitals. An RA diagnosis was confirmed using one of four gold standard definitions. Positive predictive values (PPVs) were calculated for prevalent (regardless of baseline RA‐free period) and incident (preceded by a 12‐month RA‐free period) cases.ResultsOf patients identified using claims‐based algorithms, a random sample of 389 prevalent and 134 incident cases of RA were included. Cases identified by an RA diagnosis, no diagnosis of psoriasis, and treatment with any disease‐modifying antirheumatic drugs (DMARDs) resulted in the highest PPVs versus other claims‐based treatment categories (29.0%–88.3% [prevalent] and 41.0%–78.2% [incident]); cases identified by an RA diagnosis, no diagnosis of psoriasis, and glucocorticoid‐only treatment had the lowest PPVs. Across claims‐based algorithms, PPVs were highest when a physician diagnosis or decision by adjudicators (confirmed and probable cases) was used as the gold standard and were lowest when American College of Rheumatology/European Alliance of Associations for Rheumatology 2010 criteria were applied. PPVs of claims‐based algorithms for RA in patients aged ≥66 years were slightly higher versus a USA Medicare population (maximum PPVs of 95.0% and 88.9%, respectively).ConclusionVALIDATE‐J demonstrated high PPVs for most claims‐based algorithms for diagnosis of prevalent and incident RA using Japanese claims data. These findings will help inform appropriate RA definitions for future claims database research in Japan.

Funder

Pfizer

Publisher

Wiley

Subject

Rheumatology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3